Project profile — Livestock Vaccine Innovation Fund

• Africa, regional (60.00%)
• Asia, regional (40.00%)

• Agriculture: Agricultural research (31182) (100.00%)

• Gender equality (not targeted)
• Children's issues (not targeted)
• Biodiversity (not targeted)
• Desertification (not targeted)
• Urban issues (not targeted)
• Participatory development and good governance (not targeted)
• Climate change mitigation (not targeted)
• Climate Change Adaptation (not targeted)
• Trade development (not targeted)
• Youth Issues (not targeted)
• ICT as a tool for development (not targeted)
• Indigenous Issues (not targeted)
• Environmental sustainability (cross-cutting) (not targeted)
• Disability (not targeted)

The project aims to accelerate the discovery of innovation in the development and delivery of affordable vaccines for neglected livestock diseases in Africa and Asia. Activities include: (1) researching to engineer better, and improve existing, vaccines using the latest scientific tools; (2) developing products required before taking vaccines to the market; and (3) creating public-private partnerships for the manufacture, distribution and use of vaccine innovations.

The expected intermediate outcomes of the Fund include: (1) increased dissemination of safe, effective, accessible and affordable vaccines against priority neglected livestock diseases; (2) new public-private partnerships that discover, develop and deliver affordable livestock vaccines to market for commercialization and uptake at scale.

Results achieved as of March 2020 include: (1) three calls for proposals were successfully completed, including one call under each of its three streams of activities (Upstream – vaccine development; Midstream – vaccine improvement and production; Downstream – vaccine demand, access, and adoption); (2) 24 projects have been funded, working on 16 priority diseases in 17 countries; (3) four women’s empowerment projects were launched, focusing on women’s leadership and participation in the livestock vaccine value chain; and (4) a transfer of technology from Morocco to Kenya for a Pasteurella vaccine allowed an increase in availability from 0 to 125,000 doses.

• Proactive disclosure